Drug intelligence / Profile preview

SHR0410

Development stage: Phase 3
Lead developer: Atridia
Modality: Small Molecules
Administration: Intravenous

Overview

SHR0410 is a small molecule drug that acts as a κ-opioid receptor agonist. It is being developed primarily for analgesic and antipruritic indications. The mechanism of action involves selective activation of the kappa opioid receptor, which modulates pain and itch signaling pathways. Developed by Atridia, a subsidiary of Jiangsu Hengrui Medicine (also known as Jiangsu Hengrui Pharmaceuticals), SHR0410 is under clinical development mainly for postoperative pain management and pruritus associated with hemodialysis patients. Clinical trials have reached Phase III for postoperative pain and Phase I/II stages for pruritus treatment. The drug is administered intravenously in injection form.

Other names: SHR 0410SHR0410SHR-0410Riminkefon

Targets

KOR (Kappa opioid receptor)

Beyond the preview

Go deeper on SHR0410.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SHR0410.

Explore the full profile